ProfileGDS5678 / 1448377_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 85% 90% 87% 78% 92% 81% 86% 87% 82% 81% 84% 84% 81% 86% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.2623285
GSM967853U87-EV human glioblastoma xenograft - Control 27.2425890
GSM967854U87-EV human glioblastoma xenograft - Control 36.6580487
GSM967855U87-EV human glioblastoma xenograft - Control 45.5575278
GSM967856U87-EV human glioblastoma xenograft - Control 57.7177792
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.6393881
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.3218586
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.5653187
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.9144482
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.9022281
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.1709784
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.2693784
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.7883281
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.5502986